Clinical Trial Update: Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating hydroxyurea in combination with magnesium pidolate for sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Magnesium pidolate (magnesium pidolate)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Anemia, Sickle Cell | Phase 1 | Status: COMPLETED